SB2013 L04gr5: Difference between revisions
Julia Joseph (talk | contribs) |
Julia Joseph (talk | contribs) |
||
| Line 51: | Line 51: | ||
=VlsE as a Diagnostic Tool= | =VlsE as a Diagnostic Tool= | ||
== ''IR 6''== | == ''IR 6''== | ||
IR6 is instrumental in the serodiagnosis of Lyme disease in its early stages. The sensitivity and precision of ELISA was measured based on a 26-mer synthetic peptide (C6) whose sequence matched that of IR6.<ref name="Marangoni" /> Serum samples in nonhuman primates that were introduced to different strains of ''B. burgdorferi'' were assessed for antibody responses. Antibody [http://en.wikipedia.org/wiki/Immunoglobulin_G IgG]was present in high levels for all animals over a 160-week period following infection. Human patients assessed with the C6 ELISA yielded 74% detection sensitivity in the acute disease type, 90% in the convalescent (recovery) phase, 95% in the early disseminated phase, and 100% in late Lyme disease. No antibody responses to peptides resembling the sequences of the remaining IRs were detected in humans or monkeys | IR6 is instrumental in the serodiagnosis of Lyme disease in its early stages. The sensitivity and precision of ELISA was measured based on a 26-mer synthetic peptide (C6) whose sequence matched that of IR6.<ref name="Marangoni" /> Serum samples in nonhuman primates that were introduced to different strains of ''B. burgdorferi'' were assessed for antibody responses. Antibody [http://en.wikipedia.org/wiki/Immunoglobulin_G IgG]was present in high levels for all animals over a 160-week period following infection. Human patients assessed with the C6 ELISA yielded 74% detection sensitivity in the acute disease type, 90% in the convalescent (recovery) phase, 95% in the early disseminated phase, and 100% in late Lyme disease. No antibody responses to peptides resembling the sequences of the remaining IRs were detected in humans or monkeys.<ref name="Liang" /> | ||
==''N- and C- Terminal Regions''== | ==''N- and C- Terminal Regions''== | ||